Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Press release: Sanofi successfully prices €1.5 billion bond issue Provided by GlobeNewswire Jun 17, 2025, 4:40:00 AM ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment, according to a ...

The FDA has approved Regeneron’s and Sanofi’s Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older who remain symptomatic despite treatment ...

Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use of Dupixent ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one ...

For these patients, dupilumab is a welcome addition to the COPD-treatment armamentarium, he said. The approval was based on data from a pair of phase 3 studies known as BOREAS and NOTUS.

Regeneron Pharmaceuticals Inc. and Sanofi announced the FDA approval of dupilumab for adolescents aged 12 to 17 years with chronic rhinosinusitis with nasal polyps.Dupilumab (Dupixent), a fully ...